Researchers have created a nanoparticle “super vaccine” that prevented tumor formation in up to 88% of mice. Unlike traditional vaccines that use a single signal to alert the immune system, this new approach mimics a real infection, triggering a strong, body-wide immune response.
The key is the lipid nanoparticle delivery system, which carries two immune-activating molecules (STING and TLR4 agonists) together. This combination activates multiple immune pathways at once, helping the immune system recognize and attack cancer cells more effectively.
In lab tests, the vaccine prevented tumors in mice with pancreatic cancer (88% tumor-free), triple-negative breast cancer (75%), and melanoma (69%). Even when researchers introduced cancer cells into the bloodstream to mimic metastasis, vaccinated mice stayed 100% tumor-free, showing the vaccine can create long-lasting, body-wide immune memory.
The vaccine works by training specialized T-cells to patrol the body and destroy early cancer cells before they can spread. Researchers have launched a startup, NanoVax Therapeutics, to develop the vaccine for humans. Future plans include testing it as a treatment for existing cancers and potentially as a preventative shot for high-risk individuals.